Literature DB >> 30333152

Genetic and Epigenetic Determinants of Aggressiveness in Cribriform Carcinoma of the Prostate.

Habiba Elfandy1,2, Joshua Armenia3, Filippo Pederzoli4, Eli Pullman5, Nelma Pertega-Gomes1, Nikolaus Schultz6, Kartik Viswanathan7, Aram Vosoughi7,8, Mirjam Blattner8,9, Konrad H Stopsack10, Giorgia Zadra1,11, Kathryn L Penney12,13, Juan Miguel Mosquera7,8, Svitlana Tyekucheva14,15, Lorelei A Mucci12, Christopher Barbieri8,9, Massimo Loda16,11,17.   

Abstract

Among prostate cancers containing Gleason pattern 4, cribriform morphology is associated with unfavorable clinicopathologic factors, but its genetic features and association with long-term outcomes are incompletely understood. In this study, genetic, transcriptional, and epigenetic features of invasive cribriform carcinoma (ICC) tumors were compared with non-cribriform Gleason 4 (NC4) in The Cancer Genome Atlas (TCGA) cohort. ICC (n = 164) had distinctive molecular features when compared with NC4 (n = 102). These include: (i) increased somatic copy number variations (SCNV), specifically deletions at 6q, 8p and 10q, which encompassed PTEN and MAP3K7 losses and gains at 3q; (ii) increased SPOP mut and ATMmut ; (iii) enrichment for mTORC1 and MYC pathways by gene expression; and (iv) increased methylation of selected genes. In addition, when compared with the metastatic prostate cancer, ICC clustered more closely to metastatic prostate cancer than NC4. Validation in clinical cohorts and genomically annotated murine models confirmed the association with SPOPmut (n = 38) and PTENloss (n = 818). The association of ICC with lethal disease was evaluated in the Health Professionals Follow-up Study (HPFS) and Physicians' Health Study (PHS) prospective prostate cancer cohorts (median follow-up, 13.4 years; n = 818). Patients with ICC were more likely to develop lethal cancer [HR, 1.62; 95% confidence interval (CI), 1.05-2.49], independent from Gleason score (GS). IMPLICATIONS: ICC has a distinct molecular phenotype that resembles metastatic prostate cancer and is associated with progression to lethal disease. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2018        PMID: 30333152      PMCID: PMC6359952          DOI: 10.1158/1541-7786.MCR-18-0440

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  48 in total

1.  Distinct DNA methylation alterations are associated with cribriform architecture and intraductal carcinoma in Gleason pattern 4 prostate tumors.

Authors:  Ekaterina Olkhov-Mitsel; Farshid Siadat; Ken Kron; Liyang Liu; Andrea J Savio; John Trachtenberg; Neil Fleshner; Theodorus van der Kwast; Bharati Bapat
Journal:  Oncol Lett       Date:  2017-05-09       Impact factor: 2.967

2.  Cribriform growth is highly predictive for postoperative metastasis and disease-specific death in Gleason score 7 prostate cancer.

Authors:  Charlotte F Kweldam; Mark F Wildhagen; Ewout W Steyerberg; Chris H Bangma; Theodorus H van der Kwast; Geert J L H van Leenders
Journal:  Mod Pathol       Date:  2014-09-05       Impact factor: 7.842

3.  Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer.

Authors:  Christopher E Barbieri; Sylvan C Baca; Michael S Lawrence; Francesca Demichelis; Mirjam Blattner; Jean-Philippe Theurillat; Thomas A White; Petar Stojanov; Eliezer Van Allen; Nicolas Stransky; Elizabeth Nickerson; Sung-Suk Chae; Gunther Boysen; Daniel Auclair; Robert C Onofrio; Kyung Park; Naoki Kitabayashi; Theresa Y MacDonald; Karen Sheikh; Terry Vuong; Candace Guiducci; Kristian Cibulskis; Andrey Sivachenko; Scott L Carter; Gordon Saksena; Douglas Voet; Wasay M Hussain; Alex H Ramos; Wendy Winckler; Michelle C Redman; Kristin Ardlie; Ashutosh K Tewari; Juan Miguel Mosquera; Niels Rupp; Peter J Wild; Holger Moch; Colm Morrissey; Peter S Nelson; Philip W Kantoff; Stacey B Gabriel; Todd R Golub; Matthew Meyerson; Eric S Lander; Gad Getz; Mark A Rubin; Levi A Garraway
Journal:  Nat Genet       Date:  2012-05-20       Impact factor: 38.330

4.  Classification of prostatic carcinomas.

Authors:  D F Gleason
Journal:  Cancer Chemother Rep       Date:  1966-03

5.  Digital quantification of five high-grade prostate cancer patterns, including the cribriform pattern, and their association with adverse outcome.

Authors:  Kenneth A Iczkowski; Kathleen C Torkko; Gregory R Kotnis; R Storey Wilson; Wei Huang; Thomas M Wheeler; Andrea M Abeyta; Francisco G La Rosa; Shelly Cook; Priya N Werahera; M Scott Lucia
Journal:  Am J Clin Pathol       Date:  2011-07       Impact factor: 2.493

Review 6.  The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System.

Authors:  Jonathan I Epstein; Lars Egevad; Mahul B Amin; Brett Delahunt; John R Srigley; Peter A Humphrey
Journal:  Am J Surg Pathol       Date:  2016-02       Impact factor: 6.394

7.  Evidence for molecular differences in prostate cancer between African American and Caucasian men.

Authors:  Francesca Khani; Juan Miguel Mosquera; Kyung Park; Mirjam Blattner; Catherine O'Reilly; Theresa Y MacDonald; Zhengming Chen; Abhishek Srivastava; Ashutosh K Tewari; Christopher E Barbieri; Mark A Rubin; Brian D Robinson
Journal:  Clin Cancer Res       Date:  2014-07-23       Impact factor: 12.531

8.  Functional activation of ATM by the prostate cancer suppressor NKX3.1.

Authors:  Cai Bowen; Jeong-Ho Ju; Ji-Hoon Lee; Tanya T Paull; Edward P Gelmann
Journal:  Cell Rep       Date:  2013-07-25       Impact factor: 9.423

9.  Deletion of 8p is an independent prognostic parameter in prostate cancer.

Authors:  Martina Kluth; Nina Nadine Amschler; Rami Galal; Christina Möller-Koop; Phillipp Barrow; Maria Christina Tsourlakis; Frank Jacobsen; Andrea Hinsch; Corinna Wittmer; Stefan Steurer; Till Krech; Franziska Büscheck; Till Sebastian Clauditz; Burkhard Beyer; Waldemar Wilczak; Markus Graefen; Hartwig Huland; Sarah Minner; Thorsten Schlomm; Guido Sauter; Ronald Simon
Journal:  Oncotarget       Date:  2017-01-03

10.  SPOP the mutation.

Authors:  Leah Rider; Scott D Cramer
Journal:  Elife       Date:  2015-10-27       Impact factor: 8.140

View more
  15 in total

Review 1.  Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Medicines (Basel)       Date:  2019-07-30

Review 2.  Genomic and phenotypic heterogeneity in prostate cancer.

Authors:  Michael C Haffner; Wilbert Zwart; Martine P Roudier; Lawrence D True; William G Nelson; Jonathan I Epstein; Angelo M De Marzo; Peter S Nelson; Srinivasan Yegnasubramanian
Journal:  Nat Rev Urol       Date:  2020-12-16       Impact factor: 14.432

3.  Prostatic adenocarcinoma CNS parenchymal and dural metastases: alterations in ERG, CHD1 and MAP3K7 expression.

Authors:  D Ryan Ormond; B K Kleinschmidt-DeMasters; Daniel Cavalcante; Elizabeth E Smith; Scott D Cramer; M Scott Lucia
Journal:  J Neurooncol       Date:  2019-01-17       Impact factor: 4.130

Review 4.  Oncological outcomes of cribriform histology pattern in prostate cancer patients: a systematic review and meta-analysis.

Authors:  Giorgio Ivan Russo; Timo Soeterik; Ignacio Puche-Sanz; Giuseppe Broggi; Arturo Lo Giudice; Cosimo De Nunzio; Riccardo Lombardo; Giancarlo Marra; Giorgio Gandaglia
Journal:  Prostate Cancer Prostatic Dis       Date:  2022-10-10       Impact factor: 5.455

5.  MAP3K7 Loss Drives Enhanced Androgen Signaling and Independently Confers Risk of Recurrence in Prostate Cancer with Joint Loss of CHD1.

Authors:  Leah C Rider; Lindsey U Rodrigues; Lauren K Jillson; Lina Romero; Anis Karimpour-Fard; Cera Nieto; Claire Gillette; Kathleen Torkko; Etienne Danis; Elizabeth E Smith; Rosalie Nolley; Donna M Peehl; M Scott Lucia; James C Costello; Scott D Cramer
Journal:  Mol Cancer Res       Date:  2021-04-12       Impact factor: 5.852

Review 6.  Cribriform Prostate Cancer: Clinical Pathologic and Molecular Considerations.

Authors:  Amanda B Hesterberg; Jennifer B Gordetsky; Paula J Hurley
Journal:  Urology       Date:  2021-05-28       Impact factor: 2.633

7.  Prostate cancer growth patterns beyond the Gleason score: entering a new era of comprehensive tumour grading.

Authors:  Geert J L H van Leenders; Esther I Verhoef; Eva Hollemans
Journal:  Histopathology       Date:  2020-09-13       Impact factor: 5.087

8.  A distinct repertoire of cancer-associated fibroblasts is enriched in cribriform prostate cancer.

Authors:  Amanda B Hesterberg; Brenda L Rios; Elysa M Wolf; Colby Tubbs; Hong Yuen Wong; Kerry R Schaffer; Tamara L Lotan; Giovanna A Giannico; Jennifer B Gordetsky; Paula J Hurley
Journal:  J Pathol Clin Res       Date:  2021-02-18

9.  Clinical outcome comparison of Grade Group 1 and Grade Group 2 prostate cancer with and without cribriform architecture at the time of radical prostatectomy.

Authors:  Eva Hollemans; Esther I Verhoef; Chris H Bangma; John Rietbergen; Monique J Roobol; Jozien Helleman; Geert J L H van Leenders
Journal:  Histopathology       Date:  2020-04       Impact factor: 5.087

Review 10.  Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer.

Authors:  Wout Devlies; Markus Eckstein; Alessia Cimadamore; Gaëtan Devos; Lisa Moris; Thomas Van den Broeck; Rodolfo Montironi; Steven Joniau; Frank Claessens; Thomas Gevaert
Journal:  Cells       Date:  2020-11-17       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.